Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission

[1]  A. Zelenetz,et al.  Acute lymphoblastic leukemia. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  J. Baars,et al.  Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. , 2009, Blood.

[3]  J. Sierra,et al.  Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. , 2008, Blood.

[4]  F. Aversa,et al.  Competing risk analysis using R: an easy guide for clinicians , 2007, Bone Marrow Transplantation.

[5]  Y. Kodera,et al.  Serologically HLA-DR—Mismatched Unrelated Donors Might Provide a Valuable Alternative in Allogeneic Transplantation: Experience from a Single Japanese Institution , 2007, International journal of hematology.

[6]  M. Tallman,et al.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.

[7]  M. Tallman,et al.  Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. , 2005, Blood.

[8]  Y. Kodera,et al.  Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis , 2005, Bone Marrow Transplantation.

[9]  J. Klein,et al.  Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. , 2005, Chest.

[10]  J. Fay,et al.  Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. , 2005, Blood.

[11]  H. Kantarjian,et al.  Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia , 2004, Cancer.

[12]  H. Dombret,et al.  Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Foucher,et al.  Interstitial Lung Disease Induced by Drugs and Radiation , 2004, Respiration.

[14]  V. Diehl,et al.  Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Kyo,et al.  Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study , 2002, Leukemia.

[16]  H. Inoko,et al.  The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. , 2002, Blood.

[17]  L. Damon,et al.  Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Baccarani,et al.  Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. , 2002, Blood.

[19]  B. Afessa,et al.  Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.

[20]  T. Lipp,et al.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). , 2000, Hematology/oncology clinics of North America.

[21]  D. Hoelzer,et al.  New approaches to acute lymphoblastic leukemia in adults: where do we go? , 2000, Seminars in oncology.

[22]  M. Andreeff,et al.  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. V. Stone,et al.  Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .

[24]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[25]  T. Naoe,et al.  Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG). , 1998, International journal of hematology.

[26]  T. Naoe,et al.  Re: Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment , 2018, International Journal of Hematology.

[27]  F. Mandelli,et al.  Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukaemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials , 1998 .

[28]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.

[29]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[30]  R. Larson,et al.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. , 1995, Blood.

[31]  A. Gratwohl,et al.  Proposals for standardized reporting of results of bone marrow transplantation for leukaemia. , 1989, Bone marrow transplantation.

[32]  K. Sullivan,et al.  Chronic graft-versus-host disease, obliterative bronchiolitis, and graft-versus-leukemia effect: case histories. , 1989, Transplantation proceedings.

[33]  A. Rimm,et al.  Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. , 1986, Annals of internal medicine.

[34]  K. Sullivan,et al.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. , 1981, Blood.

[35]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[36]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[37]  Y. Kodera,et al.  Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation , 2006, Bone Marrow Transplantation.

[38]  N. Kröger,et al.  Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up , 2006, Bone Marrow Transplantation.

[39]  M. Vignetti,et al.  GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. , 2004, Haematologica.

[40]  L. Mele,et al.  The incidence of secondary leukemias. , 1999, Haematologica.

[41]  F. Mandelli,et al.  Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1998, British journal of haematology.

[42]  Ganser,et al.  Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. , 1988, Blood.

[43]  D.,et al.  Regression Models and Life-Tables , 2022 .